Picture of Corline Biomedical AB logo

CLBIO — Corline Biomedical AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Brief: Corline Biomedical Gets Positive Feedback From FDA Regarding Co's Planned Phase 2 Study

Dec 4 (Reuters) - Corline Biomedical AB  CLBIO.ST :
    * FDA GIVES POSITIVE FEEDBACK REGARDING CO'S PLANNED PHASE 2
STUDY
    * IS ALSO GIVEN POSSIBILITY TO CARRY OUT ITS PHASE 2 STUDY
WITH
CLINICAL TRIAL SITES ONLY IN EUROPE WHICH WILL REDUCE COSTS AND
DURATION FOR PHASE 2 CONSIDERABLY

Source text for Eikon:  ID:nGNE3jl8Yp 
Further company coverage:  CLBIO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))

Recent news on Corline Biomedical AB

See all news